Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of Remlarsen (MRG-201) in Healthy Volunteers
NCT02603224Phase 1Completed
- Sponsor
- Viridian Therapeutics
- Start
- Nov 2015
- Primary completion
- Apr 2017
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in scar comparing MRG-201 with Placebo (2 arms). Primary endpoint: Safety and tolerability of MRG-201 up to 43 days. Started Nov 2015; status: completed.
02
Drugs
remlarsen
03
Conditions
scar
Beyond the preview
Go deeper on NCT02603224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02603224.